Sleep apnoea guidelines
August 3, 2015
The Pharmaceutical Society
of Australia has launched new
guidelines which aim to promote
the standardisation of sleep apnoea
services within pharmacies.
PSA National President Joe
Demarte said the guidelines
promote “policies and protocols
designed to ensure effective
channels of communication and
collaboration between healthcare
providers,” in line with the PSA’s
ongoing recognition of the
importance of continuity of care.
The Practice guidelines for the
provision of sleep apnoea services
within pharmacy have been
developed in collaboration with
the Australasian Sleep Association,
under a memorandum of
understanding with the PSA.
Demarte said moderate-to-severe
sleep apnoea, if left untreated,
could lead to a range of health
problems including hypertension,
cardiovascular disease, stroke,
diabetes and depression.
The condition is also a safety risk
for many people including longdistance
drivers, he said.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Aug 15To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Aug 15
